Technology News and Research

RSS

Dried blood spot technology finds new role in developing lifesaving medications

The blood test procedure used on newborn infants for 40 years is finding a second life in the search for new lifesaving medications, according to an article in the current edition of Chemical & Engineering News, ACS' weekly newsmagazine.

20 Jan 2011

Biomarin commences BMN 701 Phase 1/2 trial for treatment of Pompe disease

BioMarin Pharmaceutical Inc. announced today that it has initiated a Phase 1/2 trial for BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase in development for the treatment of Pompe disease.

20 Jan 2011

Scientists determine protein structure that delivers genetic material of HIV to human cells

A team of scientists at The Scripps Research Institute and the University of Virginia has determined the structure of the protein package that delivers the genetic material of the human immunodeficiency virus to human cells.

19 Jan 2011

Boston Scientific announces merger agreement to acquire Atritech

Boston Scientific Corporation today announced the signing of a definitive merger agreement, under which the Company will acquire Atritech, a privately held company based in Plymouth, Minnesota.

19 Jan 2011

Malaria parasite caught in action on film for the first time

Australian researchers have managed to take pictures of microscopic malaria parasite as it invades a human red blood cell. This will provide a deeper understanding of the parasite’s behaviour and may help fight it. Up to 10% of the world’s population contract malaria every year and a million people, mostly pregnant women and children, die as a result of the parasite transmitted by infected mosquitoes.

19 Jan 2011

USPTO grants KL4 surfactant combination product patent to Discovery Labs

Discovery Laboratories, Inc. has been notified that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Number 7,863,241 titled "Compositions for Treatment and Prevention of Pulmonary Conditions." The patent provides broad coverage for compositions that employ a combination of certain pulmonary surfactants with a broad array of protease inhibitors, administered as either a liquid or aerosol, for treating pulmonary inflammation.

19 Jan 2011

Home blood pressure monitors can help people keep blood pressure in check

A recent research review has concluded that home blood pressure monitors can help people keep their blood pressure in check and possibly cut down on medication – as long as patients and their doctors put those home readings to good use. For years, Omron Healthcare, Inc. has reminded Americans how important home blood pressure monitoring is when it comes to reducing their risk of a heart attack or stroke, and truly wants people to take the news to heart in 2011.

19 Jan 2011

Theraclone, Pfizer enter multi-year research and development collaboration

Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today that they have entered into a multi-year research and development collaboration with Pfizer. The collaboration will use Theraclone's I-STAR™ technology to discover broadly protective monoclonal antibodies against up to four undisclosed targets in the areas of infectious disease and cancer.

19 Jan 2011

Pisgah to scale-up patent-pending form of hydrocodone

As Pisgah Laboratories, Inc. continues development of its lead abuse deterrent opioid product, it will soon begin scale-up of its patent-pending form of hydrocodone. Pisgah has developed a specialized salt form of hydrocodone which imparts abuse deterrent properties to a dosage product. Pisgah will manufacture its hydrocodone salt for clinical trials in their FDA / DEA registered facility.

19 Jan 2011

Medtech forms new 10-school company

Medtech today announced the formation of a new 10-school company that is positioned to become a leading post-secondary healthcare career education provider. The schools include four current Midwestern campuses, along with three Sanz Schools in the Washington, D.C. area and three Javelin Technical Training Centers in greater Atlanta that will adopt the Medtech name.

19 Jan 2011

Linguamatics releases new 'cloud' version of I2E text mining platform

Linguamatics, a leading provider of NLP (Natural Language Processing) based text mining software, today announced the launch of its new "cloud" (online) version of the award winning I2E text mining platform. I2E OnDemand offers smaller companies the advanced, high performance text mining capabilities that big pharma companies have been using for years.

19 Jan 2011

National Jewish Health issued method patent for desensitizing B cells

National Jewish Health has been issued a US patent claiming a method to desensitize B cells by inactivating antigen receptors on their surfaces. The method, discovered by John Cambier, PhD, Chairman of the Integrated Department of Immunology at National Jewish Health, holds promise for treatment of B-cell mediated diseases, such as lymphoma and leukemia, rheumatoid arthritis, lupus and rejection of organ transplants.

19 Jan 2011

Point Of Care Solutions introduces AMP for physicians to manage medical practices

Point of Care Solutions introduces its Agile Medical Platform, the latest integrated practice management and ambulatory Electronic Health Record system available in the United States to manage physician medical practices with a ubiquitous interface.

19 Jan 2011

Study demonstrates clinical accuracy of Masimo's noninvasive, continuous hemoglobin monitoring technology

Masimo announced today that a new clinical study demonstrating the clinical accuracy of its noninvasive and continuous hemoglobin (SpHb®) monitoring technology breakthrough was presented last week at the Society for Technology in Anesthesia (STA) Annual Meeting.

19 Jan 2011

New study provides clear data on high rate of childhood maltreatment among deaf community

A new study at Rochester Institute of Technology indicates that the incidence of maltreatment, including neglect and physical and sexual abuse, is more than 25 percent higher among deaf and hard-of-hearing children than among hearing youths. The research also shows a direct correlation between childhood maltreatment and higher rates of negative cognition, depression and post-traumatic stress in adulthood.

19 Jan 2011

Almac reports substantial progress in transitioning operations to new headquarters

Almac is making substantial progress in transitioning operations to its new headquarters in Souderton, PA, especially in the area of distribution. The new facility has been successfully shipping clinical trial materials since November, and has recently seen an increase in shipment volumes due to the added efficiencies the new building provides.

19 Jan 2011

New patented technique offers unprecedented view of DNA damage

New technology providing the first view of DNA damage throughout the entire human genome developed by Cardiff University scientists could offer a valuable new insight into the development and treatment of conditions like cancer.

19 Jan 2011

UAB study uses InQ system to evaluate effects of secondary injury components on brain cells

InQ Biosciences, a provider of innovative technologies for cell growth and research, today announced that a pre-commercial version of its InQ Cell Research System is being utilized in a University of Alabama at Birmingham study evaluating the effects of secondary injury components on brain cells.

19 Jan 2011

New GORE VIABAHN Endoprosthesis is now available in Europe

W. L. Gore & Associates today announced the European availability of the GORE VIABAHN Endoprosthesis on a lower profile delivery system. The announcement came during the Leipzig Interventional Course in Germany, where European interventionalists gathered to discuss new approaches in treating patients suffering from peripheral artery disease.

19 Jan 2011

Arrowhead increases ownership in Calando's outstanding equity to 79%

Arrowhead Research Corporation today announced that it has invested $1 million in its majority owned subsidiary, Calando Pharmaceuticals, and converted approximately $8M of Calando debt to Arrowhead into equity. Arrowhead now owns approximately 79% of Calando's outstanding equity.

19 Jan 2011